Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02432963
Title field or adapter rule
{'original_value': 'A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At
2026-10-31T23:27:23.131855+00:00
Published At
2026-10-19T00:00:00+00:00
Record Updated At
2026-10-19
Source Retrieved At
2026-10-31T22:19:02.163121+00:00
Timestamp Basis
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation
ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Solid Neoplasm", "Bladder Carcinoma", "Colon Carcinoma", "Estrogen Receptor Negative", "Head and Neck Squamous Cell Carcinoma", "Hepatocellular Carcinoma", "HER2/Neu Negative", "Melanoma", "Non-Small Cell Lung Carcinoma", "Pancreatic Carcinoma", "Progesterone Receptor Negative", "Rectal Carcinoma", "Renal Cell Carcinoma", "Soft Tissue Sarcoma", "Triple-Negative Breast Carcinoma", "TP53 Gene Mutation", "Unresectable Solid Neoplasm"]
protocolSection.statusModule.lastUpdatePostDateStruct
{"date": "2026-10-19", "type": "ACTUAL"}
protocolSection.identificationModule.nctId
"NCT02432963"
protocolSection.identificationModule.officialTitle
"A Phase I Study of a p53MVA Vaccine in Combination With Pembrolizumab"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct
null

Study condition terms

  • Adult Solid Neoplasm (protocolSection.conditionsModule.conditions)
  • Bladder Carcinoma (protocolSection.conditionsModule.conditions)
  • Colon Carcinoma (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Negative (protocolSection.conditionsModule.conditions)
  • Head and Neck Squamous Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • HER2/Neu Negative (protocolSection.conditionsModule.conditions)
  • Melanoma (protocolSection.conditionsModule.conditions)
  • Non-Small Cell Lung Carcinoma (protocolSection.conditionsModule.conditions)
  • Pancreatic Carcinoma (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor Negative (protocolSection.conditionsModule.conditions)
  • Rectal Carcinoma (protocolSection.conditionsModule.conditions)
  • Renal Cell Carcinoma (protocolSection.conditionsModule.conditions)
  • Soft Tissue Sarcoma (protocolSection.conditionsModule.conditions)
  • Triple-Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • TP53 Gene Mutation (protocolSection.conditionsModule.conditions)
  • Unresectable Solid Neoplasm (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

  • {'armGroupLabels': ['Treatment (p53MVA, pembrolizumab)'], 'description': 'Correlative studies', 'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (p53MVA, pembrolizumab)'], 'description': 'Given SC', 'name': 'Modified Vaccinia Virus Ankara Vaccine Expressing p53', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
  • {'armGroupLabels': ['Treatment (p53MVA, pembrolizumab)'], 'description': 'Given IV', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.